EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy

Laura Soumoy, Aline Genbauffe iD, Dorianne Sant'Angelo, Maude Everaert, Léa Mukeba-Harchies, Jean-Emmanuel Sarry iD, Anne-Emilie Declèves iD, Fabrice Journe iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Laura Soumoy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Human Anatomy & Experimental Oncology, Faculty of Medicine, Pharmacy and Biomedical Sciences, Research Institute for Health Sciences an…. Hauptthemen laut MEDLINE: Melanoma, Glutaminase, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the University of Mons, the Health Institute of the University of Mons, the FRMH, "Les amis de l'Institut Bordet" from the Jules Bor…, University of Mons.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapy with BRAFi has significantly improved outcomes for patients with BRAF-mutated metastatic melanoma. However, resistance mechanisms, particularly metabolic adaptations, such as increased glutaminolysis, present substantial clinical challenges. This study investigated the metabolic changes underlying BRAFi resistance in melanoma cells. Using pharmacological agents, including dabrafenib (BRAFi), pimasertib (MEKi), dasatinib (cKITi), and CB-839 (glutaminase inhibitor), we explored metabolic adaptations in melanoma cell lines harboring various mutations. Our methodologies included cell culture, qPCR, polysome profiling, animal studies in nude mice, and analyses of patient samples to evaluate the therapeutic potential of targeting glutaminolysis. Our findings confirmed that melanoma cells, with resistance to targeted therapies, exhibit metabolic adaptations, including enhanced glutaminolysis, increased mitochondrial content, and elevated antioxidative capacities. We evaluated the efficacy of CB-839 and demonstrated its ability to reduce the proliferation of resistant melanoma cells both in vitro and in vivo. Mechanistic studies revealed that CB-839 suppressed ATP production and TCA cycle intermediates in resistant cells while inducing oxidative stress in sensitive cells, thereby inhibiting their proliferation. High glutaminase expression in primary patient tumor samples was associated with poor prognosis. We identified a metabolic signature in tumors from patients responsive or unresponsive to BRAFi prior to treatment, which could serve as a predictive factor for BRAFi response. This study underscores the metabolic alterations driving resistance to BRAFi in melanoma cells and highlights the therapeutic potential of targeting glutaminolysis with CB-839. The identification of metabolic signatures in patient samples provides valuable insights for personalized treatment strategies, aiming to overcome resistance mechanisms and improve patient outcomes in melanoma management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaGlutaminaseDrug Resistance, NeoplasmHumansAnimalsCell Line, TumorMiceMice, NudeCell ProliferationBenzeneacetamidesProto-Oncogene Proteins B-rafXenograft Model Antitumor AssaysThiadiazolesOximesMolecular Targeted TherapyAntineoplastic Agents

Stichwörter der Autor:innen

BRAF inhibitorsCB-839glutaminase inhibitionmelanoma resistancemetabolic adaptationspersonalized therapy

Substanzen

GlutaminaseCB-839BenzeneacetamidesProto-Oncogene Proteins B-rafThiadiazolesOximesAntineoplastic Agents

Autor:innen und Institutionen

  • Laboratory of Human Anatomy & Experimental Oncology, Faculty of Medicine, Pharmacy and Biomedical Sciences, Research Institute for Health Sciences and Technology, University of Mons, 7000 Mons, Belgium.
  • INSERM U981, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
  • Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm, CNRS, 31100 Toulouse, France.
  • Laboratory of Metabolic and Molecular Biochemistry, Faculty of Medicine, Pharmacy and Biomedical Sciences, Research Institute for Health Sciences and Technology, University of Mons, 7000 Mons, Belgium.
  • Laboratory of Clinical and Experimental Oncology, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium.

ORCID-Profile: Aline Genbauffe, Jean-Emmanuel Sarry, Anne-Emilie Declèves, Fabrice Journe

Förderung

  • This work was supported by the University of Mons, the Health Institute of the University of Mons, the FRMH, "Les amis de l'Institut Bordet" from the Jules Bor…
  • University of Mons

Zitieren

APA

Soumoy, L., Genbauffe, A., Sant'Angelo, D., Everaert, M., Mukeba-Harchies, L., Sarry, J. E., Declèves, A. E., & Journe, F. (2025). Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178241

Vancouver

Soumoy L, Genbauffe A, Sant'Angelo D, Everaert M, Mukeba-Harchies L, Sarry JE, et al. Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178241

BibTeX
@article{Soumoy2025,
  author = {Soumoy, Laura and Genbauffe, Aline and Sant'Angelo, Dorianne and Everaert, Maude and Mukeba-Harchies, Léa and Sarry, Jean-Emmanuel and Declèves, Anne-Emilie and Journe, Fabrice},
  title = {Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178241}
}
Kostenlos starten →